Axonics Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Axonics (NASDAQ: AXNX) reported strong financial results for Q2 2024, with record revenue of $114.6 million, up 23% year-over-year. The company achieved significant milestones:

- Sacral neuromodulation revenue: $91.2 million (+23%)
- Bulkamid revenue: $23.4 million (+25%)
- Gross margin: 77.8% (up from 75.6%)
- Net income: $6.9 million (vs. $7.3 million loss in Q2 2023)
- Adjusted EBITDA: $23.4 million (vs. $18.4 million in Q2 2023)

CEO Raymond W. Cohen attributed the growth to higher utilization at existing customers, new account onboarding, and improved manufacturing yields. The company remains confident in its market expansion strategy and looks forward to its future as part of Boston Scientific.

Positive

• Record quarterly revenue of $114.6 million, up 23% year-over-year
• Sacral neuromodulation revenue increased 23% to $91.2 million
• Bulkamid revenue grew 25% to $23.4 million
• Gross margin expanded to 77.8% from 75.6% in the prior year
• Achieved net income of $6.9 million, compared to a net loss in Q2 2023
• Adjusted EBITDA increased to $23.4 million from $18.4 million year-over-year
• Strong cash position with $362 million in cash and investments

Negative

• Operating expenses increased to $85.5 million from $82.3 million in the prior year period

Insights

Financial Analyst

Axonics' Q2 2024 results demonstrate robust financial performance, marking a significant milestone in the company's growth trajectory. The 23% year-over-year revenue growth to $114.6 million is impressive, particularly in the medical technology sector. What's even more noteworthy is the company's transition from a net loss of $7.3 million in Q2 2023 to a net income of $6.9 million in Q2 2024, signaling a pivotal shift towards profitability.

The gross margin improvement from 75.6% to 77.8% year-over-year is a strong indicator of operational efficiency and scaling benefits. This, coupled with the increase in Adjusted EBITDA from $18.4 million to $23.4 million, suggests that Axonics is successfully leveraging its growth to improve profitability.

The company's strong cash position of $362 million provides ample liquidity for future investments and potential market expansion. However, investors should note the slight increase in operating expenses from $82.3 million to $85.5 million, which appears to be well-managed given the revenue growth.

Overall, Axonics' Q2 results paint a picture of a company on a solid growth trajectory with improving profitability metrics, positioning it well for future expansion and potential market leadership in the sacral neuromodulation space.

Medical Research Analyst

Axonics' Q2 2024 results underscore the growing adoption of its sacral neuromodulation and Bulkamid therapies for bladder and bowel dysfunction. The 23% growth in sacral neuromodulation revenue to $91.2 million indicates increasing physician confidence and patient acceptance of this minimally invasive treatment option. Similarly, the 25% growth in Bulkamid revenue to $23.4 million suggests a rising preference for this urethral bulking agent in treating stress urinary incontinence.

The company's focus on innovation and quality is likely driving higher utilization rates among existing customers and attracting new accounts. This strategy aligns well with the evolving landscape of minimally invasive treatments in urology and gynecology. The mention of direct-to-consumer advertising is particularly intriguing, as it suggests Axonics is actively working to increase patient awareness and demand for its therapies, potentially expanding the overall market for sacral neuromodulation.

The pending acquisition by Boston Scientific could significantly accelerate Axonics' market penetration and global reach. This combination could lead to synergies in research and development, potentially resulting in next-generation therapies for bladder and bowel dysfunction. However, it will be important to monitor how this integration affects Axonics' agility and innovation pace, which have been key drivers of its success to date.

Generated record revenue, gross margin and net income in 2Q24

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2024.

“Axonics continued to execute at a high level in the second quarter, generating record revenue and setting new high-water marks for gross margin and adjusted EBITDA margin,” said Raymond W. Cohen, chief executive officer. “Revenue growth of 23% year over year was driven by higher utilization at existing customers and the onboarding of new accounts. Axonics also generated record net income in the second quarter, a result of gross margin expansion from higher manufacturing yields and continued operating leverage.”

Mr. Cohen continued, “We remain confident that our commitment to innovation, quality, direct-to-consumer advertising and providing strong clinical support will continue to expand the sacral neuromodulation market and propel Axonics on its path to market leadership. We look forward to the global impact the Axonics portfolio of life-changing incontinence therapies can make as part of Boston Scientific as we endeavor to treat more patients than ever before.”

Second Quarter 2024 Financial Results

• Net revenue was $114.6 million, an increase of 23% compared to the prior year period.
  • Sacral neuromodulation revenue was $91.2 million, an increase of 23% compared to the prior year period.
  • Bulkamid revenue was $23.4 million, an increase of 25% compared to the prior year period.
• Gross margin was 77.8% compared to 75.6% in the prior year period.
• Operating expenses were $85.5 million compared to $82.3 million in the prior year period.
• Net income was $6.9 million compared to a net loss of $7.3 million in the prior year period.
• Adjusted EBITDA was $23.4 million compared to $18.4 million in the prior year period.
• Cash, cash equivalents, short-term investments and restricted cash were $362 million as of June 30, 2024.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022.

Axonics^® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.

Use of Non-GAAP Financial Measures

To supplement Axonics’ consolidated financial statements prepared in accordance with generally accepted accounting principles (GAAP), Axonics provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, stock-based compensation expense, acquisition-related costs, cash compensation in lieu of equity compensation due to pending merger, acquired in-process research and development expense, loss on disposal of property and equipment, and expense related to impairment of intangible assets. Management believes that in order to properly understand short-term and long-term financial trends, investors may want to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Loss to Adjusted EBITDA” later in this release.

The non-GAAP financial measures used by Axonics may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Axonics’ financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “endeavor,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: Axonics’ ability to consummate the transactions contemplated by the Agreement and Plan of Merger, dated January 8, 2024 (the “Merger Agreement”), by and among Axonics, Boston Scientific Corporation (“Boston Scientific”), and Sadie Merger Sub, Inc., a wholly owned subsidiary of Boston Scientific (“Merger Sub”), providing for the merger of Merger Sub with and into Axonics with Axonics continuing as the surviving company and a wholly owned subsidiary of Boston Scientific (the “Merger”), in a timely manner or at all; the risk that the Merger Agreement may be terminated in circumstances requiring the payment by Axonics of a termination fee; the satisfaction (or waiver) of the conditions to the closing of the Merger; potential delays in consummating the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the Merger Agreement; Axonics’ ability to timely and successfully realize the anticipated benefits of the Merger; the ability to successfully integrate the businesses of Axonics and Boston Scientific; the effect of the announcement or pendency of the Merger on Axonics’ current plans, business relationships, operating results and business generally; the effect of limitations placed on Axonics’ business under the Merger Agreement; significant transaction costs and unknown liabilities; litigation or regulatory actions related to the Merger Agreement or Merger; FDA or other U.S. or foreign regulatory or legal actions or changes affecting Axonics or Axonics’ industry; the results of any ongoing or future legal proceedings, including the litigation with Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (the “Medtronic Litigation”); any termination or loss of intellectual property rights, including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics’ competitors, and the timing of these introductions and announcements; changes in macroeconomic and market conditions and volatility, including the risk of recession, inflation, supply chain constraints or disruptions and rising interest rates; and economic and market conditions in general and in the medical technology industry specifically, including the size and growth, if any, of Axonics’ markets, and risks related to other factors described under “Risk Factors” in other reports and statements filed with the U.S. Securities and Exchange Commission (“SEC”), including Axonics’ most recent Annual Report on Form 10-K, which is available on the investor relations section of Axonics’ website at www.axonics.com and on the SEC’s website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

The forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Axonics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
	June 30,				December 31,
		2024				2023
	(unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	168,619			$	104,811
Short-term investments		174,792				240,149
Accounts receivable, net of allowance for credit losses of $1,111 and $442 at June 30, 2024 and December 31, 2023, respectively		57,221				57,243
Inventory, net		105,428				79,940
Prepaid expenses and other current assets		6,003				9,279
Total current assets		512,063				491,422
Restricted cash		18,629				12,714
Property and equipment, net		18,382				10,760
Intangible assets, net		76,333				81,375
Other assets		23,183				24,235
Goodwill		98,747				99,417
Total assets	$	747,337			$	719,923
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	19,316			$	18,452
Accrued liabilities		11,042				10,527
Accrued compensation and benefits		24,793				15,060
Operating lease liabilities, current portion		2,022				1,777
Total current liabilities		57,173				45,816
Operating lease liabilities, net of current portion		30,431				25,840
Deferred tax liabilities, net		16,417				10,703
Total liabilities		104,021				82,359
Commitments and contingencies
Stockholders’ equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023		—				—
Common stock, par value $0.0001, 75,000,000 shares authorized at June 30, 2024 and December 31, 2023; 51,014,562 and 50,770,520 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		5				5
Additional paid-in capital		1,052,429				1,033,778
Accumulated deficit		(392,565	)			(380,352	)
Accumulated other comprehensive loss		(16,553	)			(15,867	)
Total stockholders’ equity		643,316				637,564
Total liabilities and stockholders’ equity	$	747,337			$	719,923

Axonics, Inc.
Consolidated Statements of Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Net revenue	$	114,565			$	92,894			$	205,974			$	163,544
Cost of goods sold		25,422				22,704				47,578				40,854
Gross profit		89,143				70,190				158,396				122,690
Operating expenses
Research and development		12,792				8,949				23,848				17,005
General and administrative		16,327				10,713				31,431				22,881
Sales and marketing		51,444				44,270				107,635				86,924
Amortization of intangible assets		2,247				2,279				4,501				4,501
Acquisition-related costs		2,652				602				6,479				2,368
Acquired in-process research & development		—				15,447				—				15,447
Total operating expenses		85,462				82,260				173,894				149,126
Income (loss) from operations		3,681				(12,070	)			(15,498	)			(26,436	)
Other income (expense)
Interest and other income		4,702				4,250				8,675				7,878
Interest and other expense		(32	)			174				(91	)			857
Other income, net		4,670				4,424				8,584				8,735
Income (loss) before income tax expense (benefit)		8,351				(7,646	)			(6,914	)			(17,701	)
Income tax expense (benefit)		1,452				(304	)			5,299				(1,111	)
Net income (loss)		6,899				(7,342	)			(12,213	)			(16,590	)
Foreign currency translation adjustment		466				3,750				(686	)			6,821
Comprehensive income (loss)	$	7,365			$	(3,592	)		$	(12,899	)		$	(9,769	)
Net income (loss) per share, basic	$	0.14			$	(0.15	)		$	(0.24	)		$	(0.34	)
Weighted-average shares used to compute basic net income (loss) per share		50,010,380				49,088,373				50,971,867				48,835,135
Net income (loss) per share, diluted	$	0.13			$	(0.15	)		$	(0.24	)		$	(0.34	)
Weighted-average shares used to compute diluted net income (loss) per share		51,230,849				49,088,373				50,971,867				48,835,135

Axonics, Inc.
Net Revenue by Product and Region
(in thousands)
(unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Sacral neuromodulation
United States	$	89,076			$	72,205			$	158,916			$	126,058
International		2,139				1,983				3,978				3,288
Sacral neuromodulation total	$	91,215			$	74,188			$	162,894			$	129,346
Bulkamid
United States	$	18,306			$	14,806			$	33,525			$	26,419
International		5,044				3,900				9,555				7,779
Bulkamid total	$	23,350			$	18,706			$	43,080			$	34,198
Total net revenue	$	114,565			$	92,894			$	205,974			$	163,544

Axonics, Inc.
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
(in thousands)
(unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
GAAP Net income (loss)	$	6,899			$	(7,342	)		$	(12,213	)		$	(16,590	)
Non-GAAP Adjustments:
Interest and other income		(4,702	)			(4,250	)			(8,675	)			(7,878	)
Interest and other expense		32				(174	)			91				(857	)
Income tax expense (benefit)		1,452				(304	)			5,299				(1,111	)
Depreciation and amortization expense		2,901				3,228				6,083				6,041
Stock-based compensation expense		8,611				11,204				18,162				21,918
Acquisition-related costs		2,652				602				6,479				2,368
Cash compensation in lieu of equity compensation due to pending merger		5,591				—				11,182				—
Acquired in-process research & development		—				15,447				—				15,447
Adjusted EBITDA	$	23,436			$	18,411			$	26,408			$	19,338

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240801925417/en/

Axonics contact:

Neil Bhalodkar

IR@axonics.com

Source: Axonics, Inc.

FAQ

What was Axonics' (AXNX) revenue for Q2 2024?

Axonics reported record revenue of $114.6 million for Q2 2024, representing a 23% increase compared to the same period in the previous year.

How much did Axonics' (AXNX) sacral neuromodulation revenue grow in Q2 2024?

Axonics' sacral neuromodulation revenue grew by 23% to $91.2 million in Q2 2024 compared to the prior year period.

What was Axonics' (AXNX) net income for Q2 2024?

Axonics reported a net income of $6.9 million for Q2 2024, compared to a net loss of $7.3 million in the same period of the previous year.

How much cash and investments did Axonics (AXNX) have as of June 30, 2024?

As of June 30, 2024, Axonics had $362 million in cash, cash equivalents, short-term investments, and restricted cash.